Novo Nordisk A/S

CSE:NOVO B

Lars Fruergaard Jorgensen is a notable Danish business executive, best known for his role as the President and CEO of Novo Nordisk A/S, a global healthcare company and leader in diabetes care. Born in 1966 in Denmark, Jorgensen's career has been predominantly linked with Novo Nordisk, where he began working in 1991. He holds a Master's degree in Business Administration (MBA) from Aarhus University in Denmark. Throughout his tenure at Novo Nordisk, he has held various positions, which have enriched his experience and understanding of the pharmaceutical industry. Prior to becoming CEO in January 2017, he served as an executive vice president and held leadership roles in areas such as IT, quality, treasury, and finance. Under Jorgensen's leadership, Novo Nordisk has continued to focus on innovation and its commitment to addressing diabetes and other serious chronic diseases. He has emphasized sustainability and access to healthcare as key priorities, steering the company towards initiatives that improve patient outcomes while also considering the environmental and social impacts of their operations. Jorgensen is recognized for his strategic insight and dedication to enhancing Novo Nordisk's global presence while maintaining its position as a leader in diabetes care. His leadership style is noted for fostering a culture of innovation, responsibility, and engagement among employees and stakeholders alike.

Mr. Karsten Munk Knudsen

Executive VP, CFO & Member of the Management Board

Karsten Munk Knudsen is a prominent executive at Novo Nordisk A/S, a leading global healthcare company headquartered in Denmark, known primarily for its innovative diabetes care products. He serves as the Chief Financial Officer (CFO) of Novo Nordisk, a role he took on after a distinguished career within the company and a strong track record in financial leadership. Knudsen joined Novo Nordisk in 1999, and over the years, he held various positions in finance and strategy. His experience includes significant roles in corporate finance, investor relations, and business leadership. Knudsen’s leadership style is noted for strategic financial planning, operational efficiency, and supporting the company’s growth objectives through sound financial management. Under his financial stewardship, Novo Nordisk has continued to strengthen its market position and expand its global reach. In addition to his role as CFO, Knudsen is known for his involvement in sustainability initiatives and contributing to the company’s commitment to social and environmental responsibility. His leadership extends to maintaining transparency with stakeholders and ensuring that Novo Nordisk’s financial strategies align with its broader mission of improving global health. Knudsen holds a Master’s degree in Economics from the University of Copenhagen, which has contributed to his deep understanding of financial systems and strategic economic planning.

Henrik Ehlers Wulff is a notable executive at Novo Nordisk A/S, a leading global healthcare company. He has been an integral part of the company for several years. Wulff joined Novo Nordisk in 1998 and has since held various roles with increasing responsibilities. His expertise spans across areas such as production, supply chain, and quality management, crucial for a company specializing in pharmaceuticals and healthcare products. One of his significant roles at Novo Nordisk was serving as the Executive Vice President of Product Supply, Quality & IT. In this capacity, Henrik Wulff was responsible for overseeing the global production, product supply chain, and quality management to ensure the high standards and efficiency expected from Novo Nordisk's operations. His leadership has been fundamental in driving the company's commitment to delivering high-quality, innovative healthcare solutions worldwide. Henrik Wulff's long-standing contribution to Novo Nordisk underscores his dedication and expertise in the pharmaceutical industry, helping steer the company towards achieving its strategic goals while maintaining its reputation for excellence in healthcare provision.

Ms. Camilla Sylvest

Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board

Camilla Sylvest is a prominent Danish business executive known for her significant contributions to Novo Nordisk A/S, a global healthcare company specializing in diabetes care and other serious chronic conditions. She joined Novo Nordisk in 1996 and has held several key positions within the company over the years. Sylvest's career at Novo Nordisk has been marked by a strong focus on international operations and strategic growth. Before assuming her current role, she served as Senior Vice President and Head of Region China, where she was instrumental in expanding Novo Nordisk's presence in one of the world's most critical healthcare markets. As an Executive Vice President, she oversees Commercial Strategy & Corporate Affairs, playing a pivotal role in shaping the company's strategic direction and ensuring the alignment of commercial activities with corporate priorities. Her work has been crucial in Novo Nordisk's efforts to enhance its global impact and adapt to changing market dynamics. Camilla Sylvest holds a Master of Science degree in Economics from the University of Southern Denmark. Her leadership style is characterized by a commitment to sustainable growth and patient-centered healthcare solutions, reflecting Novo Nordisk's broader mission of driving change to defeat diabetes and other serious chronic diseases.

Dr. Martin Holst Lange

Executive VP of Development & Member of the Management Board

Dr. Martin Holst Lange is an accomplished executive at Novo Nordisk A/S, a global healthcare company with a strong focus on diabetes care, hemophilia, growth disorders, and hormone replacement therapy. He currently serves as the Executive Vice President for Development, a role in which he is responsible for overseeing the company's global development efforts, particularly in bringing new medical treatments from discovery through to commercialization. Dr. Lange joined Novo Nordisk in 1999, and over the years, he has held various leadership positions within the company. His career at Novo Nordisk reflects a deep commitment to innovation in biomedical sciences, as well as a strategic emphasis on the development of new pharmaceutical solutions to enhance patient care. He holds medical qualifications and has a profound understanding of both scientific and commercial aspects of the pharmaceutical industry, which has enabled him to successfully lead cross-functional teams in developing new therapies. Under his leadership in the Development department, Novo Nordisk has continued to advance its pipeline with novel treatments across several therapeutic areas. His strategic vision and expertise have been instrumental in driving the company’s research and development targets and in maintaining a strong focus on sustainability and patient-centered care in drug development.

Dr. Marcus Schindler, Ph.D., is a renowned figure in the pharmaceutical industry, holding an executive position at Novo Nordisk A/S. With a strong background in pharmacology and diabetes research, Dr. Schindler serves as the Executive Vice President for Research & Early Development and Chief Scientific Officer at Novo Nordisk. In this role, he oversees the strategic direction and execution of the company's early-stage research and development efforts, focusing on innovation and scientific excellence to address unmet medical needs. Dr. Schindler joined Novo Nordisk with extensive experience in drug discovery and development, having previously held leadership roles in various pharmaceutical companies. His career is marked by significant contributions to advancing treatments for metabolic disorders, particularly in the areas of diabetes and obesity. Under his guidance, Novo Nordisk continues to expand its portfolio of groundbreaking therapies, aiming to improve the lives of patients worldwide. Throughout his career, Dr. Schindler has been committed to fostering collaborative environments that drive scientific breakthroughs. He is known for his leadership skills and ability to bridge the gap between scientific research and clinical application. His work has earned him a reputation as a thought leader in the industry, contributing to numerous publications and speaking engagements. With a deep commitment to innovation and patient care, Dr. Schindler continues to impact the field of medical research and pharmaceutical development significantly.

Maziar Mike Doustdar is a key executive at Novo Nordisk, a global healthcare company with a leading position in the treatment of diabetes. Doustdar has held various leadership positions within the company, contributing significantly to its international operations and growth strategies. He joined Novo Nordisk in 1992 and has since gained extensive experience in numerous international markets, helping to expand the company's presence globally. In his distinguished tenure, Doustdar has been particularly instrumental in overseeing operations in regions such as the Middle East, Africa, and the Asia-Pacific, which are crucial for Novo Nordisk's strategic expansion. His leadership is marked by a keen understanding of diverse markets and the ability to tailor Novo Nordisk’s strategies to meet varied healthcare needs. Doustdar's educational background and professional experience have equipped him to handle complex challenges in the global pharmaceutical industry, consistently focusing on increasing access to healthcare and improving patient outcomes. His contributions have been vital in driving Novo Nordisk’s mission to combat diabetes and other serious chronic diseases.

Douglas J. Langa is a notable executive at Novo Nordisk A/S, where he has played a significant role in the company's operations and strategic growth, especially in the U.S. market. Before assuming his roles at Novo Nordisk, Langa brought a wealth of experience from the pharmaceutical industry, having held senior positions at other major companies. Langa joined Novo Nordisk in 2011 and has held various executive roles within the organization. His leadership has been instrumental in driving the company's commercial strategy, enhancing its market presence, and fostering sustainable growth in the competitive pharmaceutical landscape. Langa is known for his strategic acumen, his ability to drive value, and his commitment to improving patients' lives through innovative healthcare solutions. In addition to his work at Novo Nordisk, Langa's industry experience includes roles with Johnson & Johnson, SmithKline Beecham, and Bristol-Myers Squibb, where he honed his expertise in sales, marketing, and operations. His educational background includes a degree in Business Administration. Throughout his career, Langa has been recognized for his dynamic leadership style and his ability to navigate complex market environments, positioning Novo Nordisk as a leader in diabetes care and other therapeutic areas.

Ludovic Helfgott is a prominent executive at Novo Nordisk A/S, a global healthcare company specializing in diabetes care and other chronic diseases. He has served as the Executive Vice President of Rare Disease, leading the company’s strategy and operations in this division. Helfgott’s career at Novo Nordisk began with a focus on expanding the company's impact in the global market, driving innovation, and enhancing patient care in the field of rare diseases. Helfgott has a wealth of experience in the pharmaceutical industry, having held various leadership roles before joining Novo Nordisk. His strategic vision and leadership capabilities are well-regarded in the industry, contributing to Novo Nordisk's reputation as a leader in healthcare solutions. Under his leadership, the Rare Disease division has strengthened its research and development efforts, working towards bringing life-enhancing treatments to patients worldwide. Throughout his career, Ludovic Helfgott has been committed to improving the lives of patients through innovative healthcare solutions, leveraging his expertise to make significant contributions to the field.

Tania Sabroe is the senior vice president of Global IT Operations & Strategy at Novo Nordisk A/S. In this role, she is responsible for overseeing the company's information technology strategies and ensuring the efficiency and security of IT operations on a global scale. Sabroe plays a crucial role in aligning Novo Nordisk's IT infrastructure with its business goals, supporting innovation, and enhancing digital capabilities across the organization. With a robust background in IT leadership, she brings extensive experience in digital transformation and operational excellence to the company. Her work supports Novo Nordisk's mission to drive advancements in healthcare and improve patient outcomes worldwide.